BioMed Central
Research article
Open Access
Assessment of the role of transcript for GATA-4 as a marker of unfavorable outcome in human adrenocortical neoplasms
Angela S Barbosa1, Luciano R Giacaglia1, Regina M Martin1,2, Berenice B Mendonca1,2 and Chin J Lin*1
Address: 1Laboratório de Hormônios e Genética Molecular LIM-42, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil and 2Unidade de Endocrinologia do Desenvolvimento, Divisão de Endocrinologia, Departamento de Clínica Médica, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Email: Angela S Barbosa - angela.barbosa@hcnet.usp.br; Luciano R Giacaglia - lucianogiacaglia@uol.com.br; Regina M Martin - reginamm@usp.br; Berenice B Mendonca - beremen@usp.br; Chin J Lin* - cjlin@bol.com.br
* Corresponding author
| Published: 07 July 2004 | Received: 29 August 2003 |
|---|---|
| BMC Endocrine Disorders 2004, 4:3 doi:10.1186/1472-6823-4-3 | Accepted: 07 July 2004 |
This article is available from: http://www.biomedcentral.com/1472-6823/4/3
@ 2004 Barbosa et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article’s original URL.
Abstract
Background: Malignant neoplasia of the adrenal cortex is usually associated with very poor prognosis. When adrenocortical neoplasms are diagnosed in the early stages, distinction between carcinoma and adenoma can be very difficult to accomplish, since there is yet no reliable marker to predict tumor recurrence or dissemination. GATA transcription factors play an essential role in the developmental control of cell fate, cell proliferation and differentiation, organ morphogenesis, and tissue-specific gene expression. Normal mouse adrenal cortex expresses GATA-6 while its malignant counterpart only expresses GATA-4. The goal of the present study was to assess whether this reciprocal change in the expression of GATA factors might be relevant for predicting the prognosis of human adrenocortical neoplasms. Since human adrenal cortices express luteinizing hormone (LH/hCG) receptor and the gonadotropins are known to up-regulate GATA-4 in gonadal tumor cell lines, we also studied the expression of LH/hCG receptor.
Methods: We conducted a study on 13 non-metastasizing (NM) and 10 metastasizing/recurrent (MR) tumors obtained from a group of twenty-two adult and pediatric patients. The expression of GATA-4, GATA-6, and LH/hCG receptor (LHR) in normal and tumoral human adrenal cortices was analysed using reverse transcriptase-polymerase chain reaction (RT-PCR) complemented by dot blot hybridization.
Results: Messenger RNA for GATA-6 was detected in normal adrenal tissue, as well as in the totality of NM and MR tumors. GATA-4, by its turn, was detected in normal adrenal tissue, in 11 out of 13 NM tumors, and in 9 of the 10 MR tumors, with larger amounts of mRNA found among those presenting aggressive clinical behavior. Transcripts for LH receptor were observed both in normal tissue and neoplasms. A more intense LHR transcript accumulation was observed on those tumors with better clinical outcome.
Conclusion: Our data suggest that the expression of GATA-6 in human adrenal cortex is not affected by tumorigenesis. GATA-4 expression is more abundant in MR tumors, while NM tumors express more intensely LHR. Further studies with larger cohorts are needed to test whether relative expression levels of LHR or GATA-4 might be used as prognosis predictors.
Background
Malignant neoplasia of the adrenal cortex is a rare patho- logical condition accounting for 0.05% - 0.2% of all can- cers [1]. These tumors are usually associated with unfavorable prognosis. Five-year survival rate of patients presenting with evidences of adjacent tissue invasion, lymph node infiltration or metastases is reported to range between 15 to 25% [2]. Distinction between localized tumors with malignant behavior and benign adrenocorti- cal neoplasms, based on clinical presentation and imag- ing studies, can be difficult [3]. Direct histopathologic analysis of tumoral samples has been widely accepted as the best available diagnostic tool to differentiate metasta- sizing and recurring from non-metastasizing and non- recurring tumors [3]. The evaluation of combined histo- logic features and establishment of specific scores, as pro- posed by Weiss [4], poses, however, some technical difficulties, even for skilled pathologists. This is particu- larly true for criteria such as nuclear grade, venous or sinu- soid invasion, and diffuse architecture [5]. It is usually difficult to interpret and manage patients with tumors presenting an intermediate Weiss score of 3, which is con- sidered a threshold value for malignancy [6]. Although high mitotic rate and DNA ploidy index may correlate with poor survival, not a single histopathologic feature has proven to be a reliable predictor of recurrence and metastasis [6-8]. Also, Weiss classification tends to be inaccurate for tumoral behavior prediction in children [9,10].
In order to provide reliable markers to predict tumoral outcome, the prognostic relevance of a wide array of genetic, molecular and immunohistochemical markers has been tested [2,3,11]. Adrenocortical malignant con- version has been associated with coordinated changes of antigen expression profile, such as undetectable levels of cytokeratins combined with high levels of vimentin [12]. Increased immunostaining index of the Ki67 antigen, which is a proliferation-associated nuclear protein, and elevated telomerase activity have also been related to more unfavorable prognosis [11,13,14].
Chromosomal instability is frequently described in asso- ciation with tumoral progression. Genetic instabilities such as gains in chromosome 3, 9 and X, as well as losses of heterozygosity of 11q13 (MEN-1 locus) [15,16], 17p13 [17,18] and 11p15 [19] have all been reported to be prog- nostically relevant for adrenocortical malignancy. The 11p15 region harbors genes such as IGF-II, H19, H-ras and p57KIP2. Overexpression of insulin-like growth factors I and II (IGF-I and IGF-II, respectively), of IGF-I receptor and of IGF-binding protein 2 has been implicated in tumor progression and acquisition of the malignant phe- notype in adrenal cortex [20,21]. Mutations of the p53 tumor suppressor (TP53) gene have been associated with
hereditary (Li-Fraumeni syndrome) and sporadic adreno- cortical tumors [22-25]. Unfortunately, none of these markers has been shown to be consistently reliable, since both conflicting results and overlaps between benign adrenal adenomas and carcinomas have been reported [20-23].
Expression of nuclear transcription factors has been recently studied, including the cAMP-dependent tran- scription factors CREM and CREB. Preliminary results, although limited by the number of cases, suggest that the lack of expression of CREB and inducible cAMP early repressors (ICERs) might be linked to a more severe out- come [26]. The role of members of another family of tran- scription factors - GATA family - in adrenocortical tumorigenesis has been assessed. This family of transcrip- tion factors constitute a group of 6 structurally related zinc finger proteins, that binds to conserved (A/T)GATA(A/G) sequences. Based on sequence homology and expression profile GATA proteins have been classified into two sub- families: the hematopoietic group and the cardiac group. The first group comprises GATA-1, GATA-2 and GATA-3, and are mainly expressed in hematopoietic stem cells. The second includes GATA-4, GATA-5 and GATA-6, which are expressed in heart, lung, gut epithelium, liver, yolk sac endoderm, gonads, adrenal cortex, hypothalamus and pituitary [27,28]. GATA factors play an essential role in the developmental control of cell fate, cell proliferation and differentiation, organ morphogenesis, and tissue-spe- cific gene expression [29-31]. High GATA-4 expression has been suggested to promote cell proliferation through an anti-apoptotic effect in mouse and human granulosa cells [32]. A decrease in GATA-4 expression is associated with follicular atresia through programmed cell death [33]. Various tumors have been associated with high expression of GATA-4 like granulosa and theca cell tumors [28], endodermal sinus tumor [34], esophageal/gastric adenocarcinomas [35], Sertoli and Leydig cell tumors [36]. Involvement of GATA-4 has been reported in mouse adrenocortical tumorigenesis [37]. Normal postnatal mouse adrenals express abundant GATA-6 mRNA, but no or little GATA-4 [37]. An opposite expression pattern, however, has been reported in mouse adrenocortical tumors, where GATA-4 is up-regulated and GATA-6 down- regulated during tumorigenesis. Using immunohisto- chemical staining, up-regulation of GATA-4 was also dem- onstrated in three human adrenocortical carcinomas, but not in normal adrenal tissue, adenomas or pheochromo- cytomas [37].
In order to assess whether this change in the pattern of GATA expression could be used in prognostic prediction for human adrenocortical neoplasm, we analysed the expression of GATA-4 and GATA-6 in 13 non-metastasiz-
| Patient | Gender | Age at Diagnosis (yr) | Follow-up (yr) | Clinical Presentation | Tumor Evolution | Weiss Score |
|---|---|---|---|---|---|---|
| 01 | M | 8 | 7.58 | V | NM | 4 |
| 02 | M | 9 | 7.58 | V | NM | 4 |
| 03 | F | 44 | 6.92 | C | NM | 0 |
| 04 | M | 2 | 3.75 | V | NM | 5 |
| 05 | F | 33 | 6.42 | C | NM | 0 |
| 06 | F | 29 | 6.42 | C | NM | 3 |
| 07 | F | 40 | 7.33 | NF | NM | 1 |
| 08 | F | 4 | 6 | V | NM | NA |
| 09 | F | 28 | 6.42 | C | NM | NA |
| 10 | F | 27 | 6.42 | H | NM | NA |
| 11 | F | 2 | 8.17 | C and V | NM | 2 |
| 12 | F | 24 | 5.92 | C | NM | 1 |
| 13 | F | 46 | 10 | C | NM | 1 |
| 14 | M | 29 | I (+) | C | MR | 8 |
| 15 | M | 30 | 0.83 (+) | F | MR | NA |
| 16 | F | 18 | 1.17 (+) | C and V | MR | 8 |
| 17 | F | 23 | 2 (+) | C and V | MR | 6 |
| 18 | F | 32 | 2.33 (+) | V | MR | NA |
| 19 | F | 29 | 3 (+) | V | MR | NA |
| 20 | F | 22 | I (+) | C and V | MR | NA |
| 21 | F | 9 | 1.17 (+) | C | MR | 7 |
| 22 | M | 2 | 6.25 | V | MR | 7 |
V: androgen-producing, C: glucocorticoid-producing, H: aldosterone-producing, NF: nonfunctioning, F: estrogen-producing, }: deceased, NM: non-metastasizing, MR: metastasizing/recurring, NA: insufficient data for Weiss score calculation.
ing and 10 metastasizing/recurrent tumors obtained from 22 patients.
Methods Patients
Tissue specimens were obtained from twenty-two patients with adrenocortical tumors (Table 1). Most of them has been followed in our service since the initial diagnosis of adrenocortical neoplasm. A fraction of these patients were referred to us after undergoing adrenalectomy. Before sur- gery, informed consent was obtained from all patients or their parents. Ages varied from 2 to 46 years at the time of diagnosis, with 6 males and 16 females. Initial clinical presentation included Cushing’s syndrome, adult female virilization, adult male feminization, hypertension, pseu- doprecocious puberty, and only one patient with a non- functional tumor (Table 1). Based on their clinical behavior adrenal tumors were classified as nonmetastasiz- ing (NM) or metastasizing/recurring (MR). Patients included in the NM group (n = 13) presented no disease recurrence or metastasis after a mean follow-up of 6.84 ± 1.44 years (Table 1). Conversely, except for patient 22, 9 patients in the MR group died within 1.56 ± 0.79 years since the initial diagnosis, after presenting tumor dissem- ination and/or recurrence (Table 1). Patient 22, whose clinical data have been previously reported [25], pre- sented two independent tumors excised from both left
and right adrenals in a two-year period. Subsequently sol- itary lung metastases were detected and surgically treated. He shows no signs of residual disease after a seven-year follow-up. A same pathologist reviewed histopathological data from all patients and, when sufficient data were avail- able, calculated Weiss scores (Table 1).
RNA extraction and cDNA synthesis
Tumor samples were immediately frozen in liquid nitro- gen at the time of surgery and stored until RNA extraction. Total RNA from tumor samples and from human adreno- cortical NCI-H295A cells was extracted using a guanidin- ium-thiocyanate-based commercial kit (TRI-Reagent, Sigma, St. Louis, MO). A commercial preparation of adult human adrenal total RNA (Human Adrenal Gland Total RNA, Clontech, Palo Alto, CA) was used as normal con- trol. Five micrograms of total RNA from each sample were treated with 0.5 U of DNAse I, (Promega Corp., Madison, WI) for 30 min at 37℃. DNAse-treated RNAs were reversely transcribed at 42℃ for 75 min with 200 U of a RNase H- MMLV reverse transcriptase (Superscript II, Life Technologies Inc. Gaithersburg, MD) in a final volume of 20 ul containing 50 mM Tris-HCl, pH 8.3, 75 mM KCI, 3 mM MgCl2, 1 mM of each dNTP, 100 mM dithiothreitol, 0.5 µg of oligo dT (Life Technologies Inc. Gaithersburg, MD), and 30 U of RNAse inhibitor (RNasin, Promega Corp., Madison, WI).
GATA-6
GATA-4
cyclophilin
M
Ad
NCI
+
Ad
NCI
-
-
+
.
GATA-6
GATA-4
Ad
NCI
NCI
-
+
Ad
-
+
.
.
LHR
Cyclophilin
NCI
Polymerase Chain-Reaction
One tenth of RT products was amplified in a 50 ul reac- tion mix containing 20 pmol of each specific primer, 0.2 mM dNTP each, 50 mM KCl, 10 mM Tris-HCl (pH 9.3), 1.5 mM MgCl2 and 5 U Taq Polymerase (Amersham-Phar- macia, Piscataway, NJ). Twenty microliters of the PCR product were loaded on a 1.5% agarose gel for electro- phoresis and visualization with ethidium bromide. 194- bp GATA-4 and 285-bp GATA-6 cDNA fragments were amplified using oligonucleotides GATA4-F: 5’-TCCCTCT- TCCCTCCTCAAAT-3’, GATA4-R: 5’-TCAGCGTGTAAAG- GCATCTG-3’, GATA6 - F: 5’- GAGAAGATGGAAGGGAAGGG-3’, GATA6-R: 5’-TGTG- TACCAAATGGCCTCAA-3’, designed according to human GATA-4 and GATA-6 cDNA sequences (GenBank acces- sion nº D78260 and U66075, respectively). Cycling con- ditions for PCR were: 95℃, 3 min, followed by 40 cycles at 95°℃, 30 sec, 56℃, 30 sec, 72℃, 30 sec, and a final extension cycle of 7 min at 72℃. Amplification of a 234 bp fragment from the human luteinizing hormone recep- tor (LHR) transcript was accomplished using oligonucle- otides eLHR: 5’-AGACATTCCAAAGAGATTTC-3’ and LHR2101R: 5’-GCAGTTACTGATGTAACAGTTAACAC-3’. Cycling conditions were essentially the same as those described for GATA cDNA amplification except for a 50℃
annealing temperature. As we amplified only exonic sequences, samples were tested with and without reverse transcriptase in order to rule out genomic DNA contami- nation. Samples quantity and integrity were verified by amplification of a 259-bp cyclophilin cDNA fragment using oligonucleotides CYC-F: 5’-TTTCACAGAAATTAT- TCCAGGGTTT-3’ e CYC-R: 5’-CAATATTCATGCCTTCTT- TCACTT-3’. Direct sequencing was performed to confirm the identity of RT-PCR products.
Dot-blot
Fifteen microliters of GATA-4, GATA-6, LHR and cyclophi- lin PCR products were mixed with 185 uL NaOH 0.4 M, EDTA 25 mM, heated 95℃ for 2 min, and vacuum-trans- ferred onto a nylon membrane (Hybond N+, Amersham, Piscataway, NJ). Probes were generated by radioactive PCR as follows: fragments corresponding to GATA-4, GATA-6, LHR, and cyclophilin were amplified by PCR using genomic DNA as template. The amplification condi- tions and primer sets were the same as those described in the previous section. These fragments were then cloned into the pCR2.1-TOPO T.A. cloning vector (TOPO TA Cloning kit, Invitrogen, Carlsbad, CA). The identity of the desired cloned inserts was verified by direct sequencing. A second PCR was performed in a 25 ul reaction mix con-
M1 2 3 4 5 6 7 8 9 10 11 12 13 < - M
M 14 15 16 17 18 19 20 21 22ª 22b + M
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22ª
22b
-
+
taining 100 ng of plasmid (GATA-4-pCR2.1, GATA-6- pCR2.1, LHR-pCR2.1, and cyclophilin-pCR2.1), 20 pmol of M13F/R primers, 0.1 mM dNTP each, 50 mM KCl, 10 mM Tris-HCI (pH 9.3), 1.5 mM MgCl2, 0.5 ul of [a-32P] dCTP (3000 Ci/mmol), and 5 U Taq Polymerase (Amer- sham-Pharmacia, Piscataway, NJ). Cycling conditions were: 94℃, 3 min, followed by 30 cycles at 94 ℃, 30 sec, 55℃, 30 sec, 72℃, 30 sec, and a final extension cycle of 7 min at 72℃. Probes were purified using Quiaquick PCR Purification kit (Quiaquick PCR Purification kit, Qiagen GmbH, Germany) after visualization in a 6% polyacrila- mide gel. The membranes were pre-hybridized in 5 x
SSPE, 5 × Denhardt’s, 1% SDS, 5% dextran, 50% forma- mide, and ssDNA (200 µg/ml) for two hours at 42℃. The hybridization was carried out overnight at 42℃ in the same solution after addition of the probes (100 ng). Membranes were rinsed once in 2 × SSC, 0.1% SDS for 15 min at room temperature and then washed three times in 0.1 x SSC, 0.1% SDS, first at room temperature for 15 min, and twice at 65℃ for 30 and 15 min. Membranes were exposed overnight on a phosphorscreen and an autoradiography was obtained using a Storm 860 phos- phorimager (Amersham Pharmacia Biotech, Piscataway, NJ). Densitometric analysis was carried out using Image-
M 1 2 3 4 5 6 7 8 9 10 11 12 13 4 - M
Ad Ad
M 14 15 16 17 18 19 20 21 22ª 22b + M
M
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22ª
22b
-
+
Quant 2.1 software (Amersham Pharmacia Biotech, Pis- cataway, NJ). Two normalizations were performed: 1 - densitometry data from tumor samples were normalized using the optical density from respective positive control, in order to correct any variation in transferring efficiency and probe activity. 2 - optical densities of GATA-4, GATA- 6 and LHR were normalized for each tumor sample with corresponding cyclophilin densitometry data in order to obtain the relative expression levels. Intra and inter-assay coefficients of variation for GATA-4, GATA-6, and LHR are, respectively, 4.14% and 13.23%, 12.63% and 12.24%, 7.73% and 12.16%.
Statistical analysis
Relative expression of GATA-6, GATA-4 and LHR in non- mestasizing and metastasizing groups was compared using Student t test. The ability of empirically defined cut- off values of GATA-4, 6 and LHR transcripts to discrimi- nate between these two groups was verified using Chi- square test.
Results Expression of GATA-6 and GATA-4 in human adrenocortical neoplasms
The ability of both normal and tumoral human adrenal cortices and also a human adrenocortical cell line - NCI- H295A [38,39] - to express GATA-6 and GATA-4 was assessed by PCR amplification of reversely transcribed total RNA. In order to enhance the detection sensitivity and to perform quantitative analysis of GATA-6 and GATA-4 accumulation, amplification products from a sec- ond RT-PCR were then vacuum-transferred to a mem- brane and subjected to dot-blot hybridization. Both GATA-6 and GATA-4 transcripts were detectable in nor- mal adrenal and in NCI-H295A cells, with GATA-6 being more abundant than GATA-4 (Figure 1). Thus, both GATA transcripts are normally expressed in human adrenal and NCI-H295A cells. GATA-6 mRNA was detected in all 23 tumors, irrespective of their behavior (Figure 2). Sample 16 yielded no visible amplification product on agarose gel but was clearly positive for GATA-6 in dot-blot (Figure 2),
| Patient | Tumor Evolution | GATA-6 Expression | GATA-4 Expression | LHR Expression |
|---|---|---|---|---|
| 1 | NM | 2.43 | 1.09 | 0.54 |
| 2 | NM | 3.39 | 0.60 | 1.60 |
| 3 | NM | 3.58 | 1.75 | 1.60 |
| 4 | NM | 3.45 | 0.59 | 1.07 |
| 5 | NM | 3.21 | 0.05 | 1.64 |
| 6 | NM | 2.98 | 0.91 | 0.69 |
| 7 | NM | 2.59 | 0 | 0.83 |
| 8 | NM | 3.19 | 0.04 | 1.17 |
| 9 | NM | 2.62 | 0.70 | 1.00 |
| 10 | NM | 3.02 | 0.52 | 0.54 |
| 11 | NM | 3.45 | 0.14 | 3.84 |
| 12 | NM | 2.44 | 0.62 | 0.78 |
| 13 | NM | 3.11 | 0 | 1.57 |
| 14 | MR | 3.24 | 0.32 | 0.41 |
| 15 | MR | 2.30 | 3.50 | 0.44 |
| 16 | MR | 1.74 | 0.01 | 0.35 |
| 17 | MR | 2.81 | 2.50 | 0.41 |
| 18 | MR | 2.14 | 3.37 | 1.06 |
| 19 | MR | 2.61 | 2.17 | 0.33 |
| 20 | MR | 2.71 | 2.96 | 0.50 |
| 21 | MR | 2.83 | 0.12 | 0.48 |
| 22a | MR | 3.23 | 0.58 | 1.76 |
| 22b | MR | 2.07 | 2.23 | 1.83 |
Patients are identified as in Table 1. Relative expression levels were calculated normalizing optical densities of GATA-6, GATA-4 and LHR autoradiograms with corresponding cyclophilin densitometric data as described in materials and methods. Samples 22ª and 22b are tumor specimens removed from left (22a) and right (22b) adrenal of the same patient (patient 22, Table I) NM: non-metastasizing, MR: metastasizing/recurring
illustrating the higher detection sensitivity of this method. Amplification product corresponding to GATA-4 cDNA was detected in 11 out of 13 NM tumors and in 9 of the 10 MR tumors (Figure 3). Although a faint band, with the expected size for GATA-4, was visible in the lane corre- sponding to sample 16 (Figure 3), no signal was detected on dot-blot. Given the higher sensitivity and specificity of dot-blot, this sample was considered negative and the band regarded as an artifact. Densitometric analysis of the autoradiogram provided quantitative information regard- ing accumulation of GATA transcripts (Table 2). Non- metastasizing tumors expressed more GATA-6 than metastasizing ones (respectively, 3.035 ± 0.111 and 2.568 ± 0.138, p = 0.032) while an opposite pattern was observed for GATA-4 (0.539 ± 0.143 and 1.776 ± 0.384, p = 0.003).
Expression of LH/hCG receptor in human adrenocortical neoplasms
Gonadotropins have been shown to up-regulate GATA-4 in gonadal tumor cell lines [30,32]. In mouse Leydig cell lines, GATA-4 mRNA accumulation is stimulated by hCG [30]. Since LH/hCG receptor has been detected in both normal human and tumoral mouse adrenal cortices [40,41], we speculated that LHR expression might be cor-
related with the accumulation of GATA-4 in human adre- nal cortex. For this reason, we investigated the expression pattern of LH receptor in our adrenocortical specimens. Amplification products of LHR transcript were observed in all tumors, and also in normal adrenal cortex and NCI cells (Figures 1 and 4). Samples displaying more abun- dant LHR transcripts were, in their majority, NM tumors. Nevertheless, no statistically significant difference in LHR mRNA accumulation was found (1.298 + 0.24 and 0.757 ± 0.162, respectively for NM and MR groups, p = 0.209) in this group compared to the MR one. Samples expressing more abundant GATA-4 generally expressed smaller amounts of LHR (samples 15, 17, 19, 20, Figures 3, 4 and 6). Conversely, samples expressing smaller amounts of GATA-4 usually expressed LHR more intensely (samples 2, 5, 7, 8, 11, 13, Figures 3, 4 and 6).
Correlation between tumor behavior and expression of GATA-4, 6 and LHR
Since the relative expression of GATA transcripts in the NM group is different from those in the MR group (Table 2) we examined whether a cut-off value for the expression of such mRNAs could be used as a predictor of tumor behavior. In our cohort, an empirically established expres- sion level of GATA-4 above 1.77 is correlated with poor
M 1 2 3 4 5 6 7 8 9 10 11 12 13 < - M M 14 15 16 17 18 19 20 21 22ª22b + M
1
2
3
4
5
6
7
8
9
10
11
12
13
☒
14
15
16
17
18
19
20
21
22ª
22b
-
+
prognosis (p = 0.006) with a relative risk of 4.25 (95% CI: 1.508 - 4.25). Such a cut-off value, however, would lead to a false negative diagnosis of 4 out of 10 MR subjects (patients 14, 16, 21, and 22a). In contrast, no cut-off allowing a clear discrimination between favorable and unfavorable outcome could be determined for GATA-6.
We also verified whether LHR expression could serve as a predictor for tumor outcome. Although NM and MR groups showed no differences regarding the relative expression of LHR, expression below an empirical thresh- old of 0.53 was correlated with aggressive behavior (p = 0.002) with a relative risk of 5.333 (95% CI: 1.815 - 5.333). Combination of both GATA-4 and LHR did not improve any further the ability to discriminate tumoral behavior and clinical fate.
Discussion
In this report, carried out on 22 patients, we demonstrated that expression of GATA-4 in human adrenal cortex is not confined to malignant tumors, but also occurs in non- metastasizing tumors. GATA-6 transcripts were detected in all tumor samples, regardless of their biological behav- ior. We believe that the obtained RT-PCR products truly reflect the actual expression of GATA factors in those tis- sue samples and are not a result of amplification of GATA transcripts expressed in the stroma and capillaries sur- rounding the neoplastic adrenocortical cells. First, we were able to detect both GATA-6 and 4 transcripts in cul- tured human adrenal NCI-H295A cells (Figure 1), dem- onstrating that expression of these two members of the GATA family actually occurs in some cell lines of human adrenal cortex. Second, there are a number of unequivo-
M 1 2 34 567 8 910 11 12 13 < - M M 14 15 16 17 18 19 20 21 22ª 22b + M
Ad
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22ª
22b
+
-
cally GATA-4 negative tissue specimens among those we have analyzed in this study (Figure 3), suggesting that the contribution of GATA-4 from the endothelial cells and surrounding tumoral stroma on the RT-PCR signal was negligible.
The highest GATA-4 expression levels are found among the MR samples. This suggests that a high relative expres- sion of GATA-4 might be correlated with a poor outcome. Nevertheless, GATA-4 expression is not confined solely to malignant neoplasms of human adrenal cortex since 11 out of 13 NM tumors were GATA-4 positive. Our results are not consistent with a previous study, based on a model of adrenal tumorigenesis using inhibin a promoter/SV40 Tag transgenic mice, which revealed that GATA-4 was up-
regulated while GATA-6 was down-regulated in carcino- mas [37]. It is not clear why there were such differences between our data and those observed in the inhibin a pro- moter/SV40 Tag transgenic mice [37]. One possible expla- nation relies on the difference in sensitivity of the detection method. In this study, we used RT-PCR followed by dot-blot, which is more sensitive than ribonuclease protection assay for detection of gene expression. Alterna- tively, given the probable relationship between the hyper- secreted gonadotropins and adrenocortical tumorigenesis on these transgenic mice [41-43], we speculated that the reciprocal pattern of GATA-6 and 4 expression reported for this mouse model might be the result of an increased secretion of LH following gonadectomy.
Tumors expressing higher levels of GATA-4 tended to exhibit lower levels of LHR, while the opposite has also occurred. It is worth noting that both tumor samples removed from patient 22, who presented an unexpectedly benign evolution (Table 1), expressed the highest levels of LHR amongst the whole MR group (Table 2). In spite of presenting recurrent pulmonary metastases, this patient is presently alive and his disease is under control after surgi- cal excision of those metastatic lesions. This observation suggests a possible correlation between long-term survival and higher expression of LHR. It remains to be confirmed whether a higher relative expression of LHR is associated with a less aggressive disease course.
We conclude that, in opposition to experimental mouse adrenocortical tumors, expression of GATA-6 in human adrenal cortex is not affected by tumorigenesis, and per- sists in both metastasizing and non-metastasizing neo- plasms. In this small series of patients GATA-4 expression tends to be more intense in metastasizing tumors. Further studies with larger cohorts are warranted before one can reach a more definitive conclusion regarding the prognos- tic value of expression level of LHR or GATA-4 in adreno- cortical neoplasms.
Competing interests
None declared.
Authors’ contributions
A.S.B. carried out the molecular analyses, participated in the design of the study, and in the writing of the manuscript. L.R.G. reviewed the clinical data, participated in the design of the study, in the collection of specimens and in the writing of the manuscript. R.M.M. participated in the molecular analyses, and reviewed the clinical data. B.B.M. coordinated the collection of samples and the fol- low-up of the enrolled patients and participated in the design of the study. C.J.L. conceived the study, partici- pated in the molecular analyses, in the interpretation of data and in the writing of the manuscript.
Acknowledgements
This work was supported by grants from the Fundação de Amparo à Pesquisa do Estado de São Paulo, São Paulo, Brazil (grants # 00/1 1362-0 to CJL and 01/12571-5 to ASB).
References
1. Flack MR, Chrousos GP: Neoplasms of the adrenal cortex. Can- cer Medicine Edited by: Holland R. New York, Lea and Fibinger; 1996:1567-1570.
2. Latronico AC, Chrousos GP: Extensive personal experience: adrenocortical tumors. J Clin Endocrinol Metab 1997, 82:1317-1324.
3. Wajchenberg BL, Albergaria Pereira MA, Medonca BB, Latronico AC, Campos Carneiro P, Alves VA, Zerbini MC, Liberman B, Carlos Gomes G, Kirschner MA: Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000, 88:711-736.
4. Weiss LM: Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 1984, 8:163-169.
5. Aubert S, Wacrenier A, Leroy X, Devos P, Carnaille B, Proye C, Wemeau JL, Lecomte-Houcke M, Leteurtre E: Weiss system revis- ited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol 2002, 26:1612-1619.
6. Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, Ber- therat J, Chapuis Y, Duclos JM, Schlumberger M, Plouin PF, Luton JP, Le Bouc Y: Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 2001, 61:6762-6767.
7. Weiss LM, Medeiros LJ, Vickery A. L., Jr .: Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 1989, 13:202-206.
8. Haak HR, Cornelisse CJ, Hermans J, Cobben L, Fleuren GJ: Nuclear DNA content and morphological characteristics in the prog- nosis of adrenocortical carcinoma. Br J Cancer 1993, 68:151-155.
9. Mendonca BB, Lucon AM, Menezes CA, Saldanha LB, Latronico AC, Zerbini C, Madureira G, Domenice S, Albergaria MA, Camargo MH, et al .: Clinical, hormonal and pathological findings in a com- parative study of adrenocortical neoplasms in childhood and adulthood. J Urol 1995, 154:2004-2009.
10. Sredni ST, Zerbini MC: Correspondence Re: Lack EE, Askin FB, Dehner LB, Page DL, Weiss LM. Recommendations for reporting of tumors of the adrenal cortex and medulla. Mod Pathol 1999:12:835-9. Mod Pathol 2000, 13:920.
11. Wachenfeld C, Beuschlein F, Zwermann O, Mora P, Fassnacht M, Allolio B, Reincke M: Discerning malignancy in adrenocortical tumors: are molecular markers useful? Eur J Endocrinol 2001, 145:335-341.
12. Cote RJ, Cordon-Cardo C, Reuter VE, Rosen PP: Immunopathol- ogy of adrenal and renal cortical tumors. Coordinated change in antigen expression is associated with neoplastic conversion in the adrenal cortex. Am J Pathol 1990, 136:1077-1084.
13. Goldblum JR, Shannon R, Kaldjian EP, Thiny M, Davenport R, Thomp- son N, Lloyd RV: Immunohistochemical assessment of prolif- erative activity in adrenocortical neoplasms. Mod Pathol 1993, 6:663-668.
14. Hirano Y, Fujita K, Suzuki K, Ushiyama T, Ohtawara Y, Tsuda F: Tel- omerase activity as an indicator of potentially malignant adrenal tumors. Cancer 1998, 83:772-776.
15. Skogseid B, Larsson C, Lindgren PG, Kvanta E, Rastad J, Theodorsson E, Wide L, Wilander E, Oberg K: Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1992, 75:76-81.
16. Kjellman M, Roshani L, Teh BT, Kallioniemi OP, Hoog A, Gray S, Farnebo LO, Holst M, Backdahl M, Larsson C: Genotyping of adrenocortical tumors: very frequent deletions of the MENI locus in 11q13 and of a I-centimorgan region in 2p16. J Clin Endocrinol Metab 1999, 84:730-735.
17. Yano T, Linehan M, Anglard P, Lerman MI, Daniel LN, Stein CA, Rob- ertson CN, LaRocca R, Zbar B: Genetic changes in human adrenocortical carcinomas. J Natl Cancer Inst 1989, 81:518-523.
18. Gicquel C, Bertagna X, Le Bouc Y: Recent advances in the patho- genesis of adrenocortical tumours. Eur J Endocrinol 1995, 133:133-144.
19. Gicquel C, Raffin-Sanson ML, Gaston V, Bertagna X, Plouin PF, Sch- lumberger M, Louvel A, Luton JP, Le Bouc Y: Structural and func- tional abnormalities at Ilp15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab 1997, 82:2559-2565.
20. Boulle N, Logie A, Gicquel C, Perin L, Le Bouc Y: Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding pro- tein-2 are associated with malignancy in sporadic adrenocor- tical tumors. J Clin Endocrinol Metab 1998, 83:1713-1720.
21. Weber MM, Fottner C, Wolf E: The role of the insulin-like growth factor system in adrenocortical tumourigenesis. Eur J Clin Invest 2000, 30:69-75.
22. 2. Ohgaki H, Kleihues P, Heitz PU: p53 mutations in sporadic adrenocortical tumors. Int J Cancer 1993, 54:408-410.
23. Adleff V, Racz K, Toth M, Varga I, Bezzegh A, Glaz E: p53 protein and its messenger ribonucleic acid in human adrenal tumors. J Endocrinol Invest 1998, 21:753-757.
24. Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR, DeLacerda L, Rabin M, Cadwell C, Sampaio G, Cat I, Stra- takis CA, Sandrini R: An inherited p53 mutation that contrib- utes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci U S A 2001, 98:9330-9335.
25. Latronico AC, Pinto EM, Domenice S, Fragoso MC, Martin RM, Zer- bini MC, Lucon AM, Mendonca BB: An inherited mutation out- side the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with spo- radic adrenocortical tumors. J Clin Endocrinol Metab 2001, 86:4970-4973.
26. Peri A, Luciani P, Conforti B, Baglioni-Peri S, Cioppi F, Crescioli C, Ferruzzi P, Gelmini S, Arnaldi G, Nesi G, Serio M, Mantero F, Mannelli M: Variable expression of the transcription factors cAMP response element-binding protein and inducible cAMP early repressor in the normal adrenal cortex and in adrenocortical adenomas and carcinomas. J Clin Endocrinol Metab 2001, 86:5443-5449.
27. Molkentin JD: The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tis- sue-specific gene expression. J Biol Chem 2000, 275:38949-38952. 28. Laitinen MP, Anttonen M, Ketola I, Wilson DB, Ritvos O, Butzow R, Heikinheimo M: Transcription factors GATA-4 and GATA-6 and a GATA family cofactor, FOG-2, are expressed in human ovary and sex cord-derived ovarian tumors. J Clin Endo- crinol Metab 2000, 85:3476-3483.
29. Viger RS, Mertineit C, Trasler JM, Nemer M: Transcription factor GATA-4 is expressed in a sexually dimorphic pattern during mouse gonadal development and is a potent activator of the Mullerian inhibiting substance promoter. Development 1998, 125:2665-2675.
30. Ketola I, Rahman N, Toppari J, Bielinska M, Porter-Tinge SB, Tapa- nainen JS, Huhtaniemi IT, Wilson DB, Heikinheimo M: Expression and regulation of transcription factors GATA-4 and GATA- 6 in developing mouse testis. Endocrinology 1999, 140:1470-1480.
31. I. Tremblay JJ, Viger RS: Nuclear receptor Dax-I represses the transcriptional cooperation between GATA-4 and SF-I in Sertoli cells. Biol Reprod 2001, 64:1191-1199.
32. Heikinheimo M, Ermolaeva M, Bielinska M, Rahman NA, Narita N, Huhtaniemi IT, Tapanainen JS, Wilson DB: Expression and hormo- nal regulation of transcription factors GATA-4 and GATA-6 in the mouse ovary. Endocrinology 1997, 138:3505-3514.
33. Vaskivuo TE, Anttonen M, Herva R, Billig H, Dorland M, te Velde ER, Stenback F, Heikinheimo M, Tapanainen JS: Survival of human ovarian follicles from fetal to adult life: apoptosis, apoptosis- related proteins, and transcription factor GATA-4. J Clin Endo- crinol Metab 2001, 86:3421-3429.
34. Siltanen S, Anttonen M, Heikkila P, Narita N, Laitinen M, Ritvos O, Wilson DB, Heikinheimo M: Transcription factor GATA-4 is expressed in pediatric yolk sac tumors. Am J Pathol 1999, 155:1823-1829.
35. Lin L, Aggarwal S, Glover TW, Orringer MB, Hanash S, Beer DG: A minimal critical region of the 8p22-23 amplicon in esopha- geal adenocarcinomas defined using sequence tagged site- amplification mapping and quantitative polymerase chain reaction includes the GATA-4 gene. Cancer Res 2000, 60:1341-1347.
36. Ketola I, Pentikainen V, Vaskivuo T, Ilvesmaki V, Herva R, Dunkel L, Tapanainen JS, Toppari J, Heikinheimo M: Expression of transcrip- tion factor GATA-4 during human testicular development and disease. J Clin Endocrinol Metab 2000, 85:3925-3931.
37. Kiiveri S, Siltanen S, Rahman N, Bielinska M, Lehto VP, Huhtaniemi IT, Muglia LJ, Wilson DB, Heikinheimo M: Reciprocal changes in the expression of transcription factors GATA-4 and GATA-6 accompany adrenocortical tumorigenesis in mice and humans. Mol Med 1999, 5:490-501.
38. Staels B, Hum DW, Miller WL: Regulation of Steroidogenesis in NCI-H295 Cells: A Cellular Model of the Human Fetal Adrenal. Mol Endocrinol 1993, 7:423-433.
39. Rodriguez H, Hum DW, Staels B, Miller WL: Transcription of the Human Genes for Cytochrome P450scc and P450c17 is Reg- ulated Differently in Human Adrenal NCI-H295 Cells Than in Mouse Adrenal YI Cells. J Clin Endocrinol Metab 1997, 82:365-371.
40. Pabon JE, Li X, Lei ZM, Sanfilippo JS, Yussman MA, Rao CV: Novel presence of luteinizing hormone/chorionic gonadotropin
receptors in human adrenal glands. J Clin Endocrinol Metab 1996, 81:2397-2400.
41. Rilianawati, Paukku T, Kero J, Zhang FP, Rahman N, Kananen K, Huht- aniemi I: Direct luteinizing hormone action triggers adreno- cortical tumorigenesis in castrated mice transgenic for the murine inhibin alpha-subunit promoter/simian virus 40 T- antigen fusion gene. Mol Endocrinol 1998, 12:801-809.
42. Kananen K, Markkula M, Mikola M, Rainio EM, McNeilly A, Huht- aniemi I: Gonadectomy permits adrenocortical tumorigenesis in mice transgenic for the mouse inhibin alpha-subunit pro- moter/simian virus 40 T-antigen fusion gene: evidence for negative autoregulation of the inhibin alpha-subunit gene. Mol Endocrinol 1996, 10:1667-1677.
43. Kananen K, Rilianawati, Paukku T, Markkula M, Rainio EM, Huhtanemi I: Suppression of gonadotropins inhibits gonadal tumorigen- esis in mice transgenic for the mouse inhibin alpha-subunit promoter/simian virus 40 T-antigen fusion gene. Endocrinology 1997, 138:3521-3531.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-6823/4/3/prepub
Publish with Bio Med Central and every scientist can read your work free of charge
“BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime.” Sir Paul Nurse, Cancer Research UK
Your research papers will be:
· available free of charge to the entire biomedical community
· peer reviewed and published immediately upon acceptance
· cited in PubMed and archived on PubMed Central
· yours - you keep the copyright
Submit your manuscript here: http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral